Angle Share Discussion Threads

[jelenko] 24/4/2024 09:26

SK,
Very measured comments and of course sensible but I might add that any company no matter who they are survive on cash flow. Tesco etc need shoppers every day but they don't rns the market when every customer goes through the checkout and all these small customers add up. For what it's worth I think they will move through this phase without the need to raise.
I certainly don't see the large japanese Pharma and now AZN working with a firm that may not be around in a couple of years and also I don't think that they would be recruiting at the level they are without knowing if they could pay the ongoing salaries.

[citys2874] 24/4/2024 09:15

16.00 being paid now mms lifting back up once this breaks 17.00 will move up very fast to 19.00+

[g2theary] 24/4/2024 09:14

20p is a dead certain today :)

[g2theary] 24/4/2024 09:08

Nice trade out 1st thing and back in with more shares :)

[sicilian_kan] 24/4/2024 09:07

Agreed, typo corrected.

[bagpuss67] 24/4/2024 09:06

SK. Q2 25...

[citys2874] 24/4/2024 09:03

volume crossed 3 million in the first hour trading .....buys pressure very strong .....expect mms to let go and let it it breakout very soon

[sicilian_kan] 24/4/2024 08:59

Hi Bermuda, yes the RNS is a very, very good one. Great to see an AZ deal too, which we all thought might happen given the Kyra Mumford connection. However I wouldn't be too dismissive about the financial side. Angle has to hit revenue of £6m-£7m this year [tripling 2023 revenues of £2.2m] to avoid yet another revenue warning. This RNS for £150k will not get us over that line and there has only been one other contract worth £250k announced in the past 5.5 months since the last revenue warning. Angle will also need to raise cash later this year as we only have cash into Q2 25 from recollection. So whilst this RNS is fabulous on the science side and whilst it might help generate very significant revenues further down the line, it doesn't solve the immediate revenue / cash problem that Angle has. Hopefully sales have been strong and the results will be very good, however the relative lack of large [in financial terms] contracts this calendar year gives me hesitation. I bought a few this morning, but I'm going to hold out for the results before deciding whether to increase my stake.

[citys2874] 24/4/2024 08:43

in the top 5 leaderboard risers

[wall street trader] 24/4/2024 08:38

Whatever happens today it won't stop this getting back to a quid within five years - have added more now good news is coming through regularly

[citys2874] 24/4/2024 08:37

up 28 percent very strong buying pressure today ....big pharma ...Fabulous News today

[citys2874] 24/4/2024 08:33

up 25 percent now great opening start

[citys2874] 24/4/2024 08:32

RNS OUT - Commercial contract with Astrazeneca see this hitting 20.00+ today

[bagpuss67] 24/4/2024 08:29

Especially if that potential customer is in the DDR space!

[bermudashorts] 24/4/2024 08:25

nigel,

Yes, the level of the fee is simply a function of the work inovlved to develop the assay. They will be basing it on the existing pKAP1 CTC-based DDR assay which was developed for Artois, so they're not starting from scratch.

[bagpuss67] 24/4/2024 08:16

The other thing is if you are an AGL sales person about to pick up the phone later today or make a presentation you will do so with a big spring in your step. Two big pharma names have now signed up and maybe that will be enough to push some deals that were in the balance over the line or mean that the potential customer who previously wouldn't take your call now will... Metaphorically speaking!

[gspanner] 24/4/2024 08:14

Well said Bermuda!
Olaparib is massive; breast, ovarian now prostate cancer…

[g2theary] 24/4/2024 08:13

Lovely news ;)

[wall street trader] 24/4/2024 08:11

The Gravy train has started its journey

[nigelpm] 24/4/2024 08:11

Yes Bermuda - it's a trial hence the nominal £150k.

[philjeans] 24/4/2024 08:10

Big Pharma going to take this out now!

[philjeans] 24/4/2024 08:09

SO CHEAP!

BUY.

[bermudashorts] 24/4/2024 08:08

This is a cracking RNS and if your only reaction to this news is to criticise the size of the fee then either you don't understand the significance of the contract or you are simply bashing for the sake of it. The size of the fee is irrelevant here.

The point is that the DDR pathway is one of the cornerstones of AstraZeneca's oncology strategy and they are one of the major players in the field. Astra's Olaparib was the first ever approved PARP inhibitor and has multi billion dollar sales and they continue to pour vast amounts into R&D in this area. Worth reading the link below from Astra's website to understand the importance they place on DDR development. This quote stood out:

'We are also using a range of technologies and exploratory endpoints to both develop assays to inform patient selection and monitor patient relapse, with the aim of identifying further opportunities for developing new targeted therapies. We are committed to pushing the boundaries of science and harnessing our DDR targets to achieve the best possible outcomes for patients'

If Angle are able to successfully devleop this assay, not only could it be transformational for the company, but other contracts will follow, just as this has followed the Artois contract.

It's fantastic to see Angle finally gaining some traction.

[bsg] 24/4/2024 08:07

Hardly, £150k in first six months will not pay directors fees for that period. Better than a poke in the eye though.